Open Access

Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma

  • Authors:
    • Masakazu Sato
    • Takahide Arimoto
    • Kei Kawana
    • Yuichiro Miyamoto
    • Yuji Ikeda
    • Kensuke Tomio
    • Michihiro Tanikawa
    • Kenbun Sone
    • Mayuyo Mori‑Uchino
    • Tetsushi Tsuruga
    • Kazunori Nagasaka
    • Katsuyuki Adachi
    • Yoko Matsumoto
    • Katsutoshi Oda
    • Yutaka Osuga
    • Tomoyuki Fujii
  • View Affiliations

  • Published online on: January 28, 2016     https://doi.org/10.3892/mco.2016.748
  • Pages: 492-496
  • Copyright: © Sato et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate whether measuring endometrial thickness during fertility‑sparing treatment with medroxyprogesterone acetate (MPA) can be a predictive marker for effectiveness in women with endometrioid adenocarcinoma, grade 1 (EmCa, G1). A total of 32 patients with stage IA EmCa, G1 underwent treatment with MPA. Patients were <40 years of age and preferred fertility‑sparing treatment. MPA (600 mg/day) with low‑dose aspirin was administered orally for 26 weeks. Pathological evaluation was performed by total curettage at weeks 8 and 16 and by fractional curettage at week 26. Patients underwent curative surgery in case of disease progression. Endometrial thickness was measured by transvaginal ultrasonography at weeks 8 and 16. Patients who showed non‑complete response (non‑CR) had thicker endometrium than that of CR patients at weeks 8 and 16. Receiver operating characteristic analysis revealed cut‑off values of 8.3 and 4.7 mm endometrial thickness at weeks 8 and 16, respectively, for non‑CR. Endometrial thickness >5 mm at week 16 was an independent factor for prediction of non‑CR. Measurement of endometrial thickness during MPA treatment may be useful as a predictive marker for pathological response to MPA in patients with EmCa, G1.
View Figures
View References

Related Articles

Journal Cover

April 2016
Volume 4 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sato, M., Arimoto, T., Kawana, K., Miyamoto, Y., Ikeda, Y., Tomio, K. ... Fujii, T. (2016). Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma. Molecular and Clinical Oncology, 4, 492-496. https://doi.org/10.3892/mco.2016.748
MLA
Sato, M., Arimoto, T., Kawana, K., Miyamoto, Y., Ikeda, Y., Tomio, K., Tanikawa, M., Sone, K., Mori‑Uchino, M., Tsuruga, T., Nagasaka, K., Adachi, K., Matsumoto, Y., Oda, K., Osuga, Y., Fujii, T."Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma". Molecular and Clinical Oncology 4.4 (2016): 492-496.
Chicago
Sato, M., Arimoto, T., Kawana, K., Miyamoto, Y., Ikeda, Y., Tomio, K., Tanikawa, M., Sone, K., Mori‑Uchino, M., Tsuruga, T., Nagasaka, K., Adachi, K., Matsumoto, Y., Oda, K., Osuga, Y., Fujii, T."Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma". Molecular and Clinical Oncology 4, no. 4 (2016): 492-496. https://doi.org/10.3892/mco.2016.748